Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects

Journal of Bone and Mineral Metabolism

Volumn 26, Issue 3, 2008, Pages 265-270

  Nishizawa, Yoshiki ^a   Inaba, Masaaki ^a   Ishii, Mitsukazu ^b   Yamashita, Hiroyuki ^c   Miki, Takami ^a   Goto, Hitoshi ^a   Yamada, Sinsuke ^a   Chaki, Osamu ^d   Kurasawa, Kentaro ^d   Mochizuki, Yoshiko ^e  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yoro Orthopedic Clinic   (Japan)

^c Yamashita Clinic   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Fragments absorbed immunocapture enzymatic assay (FAICEA); Osteoclastic activity; Reference interval; Tartrate resistant acid phosphatase 5b (TRACP 5b)

Indexed keywords

ACID PHOSPHATASE; TARTARIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL;

ACID PHOSPHATASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; FEMALE; HUMANS; ISOENZYMES; JAPAN; MALE; MIDDLE AGED; REFERENCE STANDARDS; REFERENCE VALUES;

EID: 43049106912     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-007-0826-0     Document Type: Article

References (36)

1. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD (1990) Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 8:87-96
2. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked Ntelopeptides in urine. J Bone Miner Res 7:1251-1258
3. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C (1994) Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025
4. Gomez B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT (1995) Monoclonal antibody assay for measuring bonespecific alkaline phosphatase activity in serum. Clin Chem 41:1560-1566
5. Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C (1997) Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 12:1028-1034
6. Clemens JD, Herrick MV, Singer FR, Eyre DR (1997) Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058-2063
7. Lau KH, Onishi T, Wergedal JE, Singer FR, Baylink DJ (1987) Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem 33:458-462
8. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337-1345
9. Igarashi Y, Lee MY, Matsuzaki S (2001) Heparin column analysis of serum type 5 tartrate-resistant acid phosphatase isoforms. J Chromatogr B Biomed Sci Appl 757:269-276
10. Ohashi T, Igarashi Y, Mochizuki Y, Miura T, Inaba N, Katayama K, Tomonaga T, Nomura F (2007) Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 376:205-212
11. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139-150
12. World Health Organization Study Group on Assessment of Fracture Risk and Its Application to Screening and Postmenopausal Osteoporosis (1994) Report of a WHO Study Group. Technical Report Series No. 84. WHO, Geneva
13. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M (2005) Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 23:97-104
14. Igarashi Y, Mochizuki Y, Miura T, Ohashi T, Sasagawa K, Katayama K, Inaba N, Matsuzaki S (2003) Evaluation of a novel immunoassay for serum tartrate-resistant acid phosphatase type 5b activity in hormone replacement therapy. Bone (NY) 32:S179
15. Mochizuki Y, Nishizawa Y, Oishi A, Otsu R, Igarashi Y, Miura T, Inaba N (2005) Day-to-day and diurnal variations of serum tartrate-resistant acid phosphatase type 5b with newly developed TRAP5b kit and their comparison to other bone resorption markers. Bone (NY) 36:S334
16. Kollerup G, Thamsborg G, Bhatia H, Sorensen OH (1992) Quantitation of urinary hydroxypyridinium cross-links from collagen by high-performance liquid chromatography. Scand J Clin Lab Invest 52:657-662
17. Garnero P, Delmas PD (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:1046-1053
18. Garnero P, Gineyts E, Riou JP, Delmas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785
19. Kushida K, Takahashi M, Kawana K, Inoue T (1995) Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80:2447-2450
20. Khosla S, Atkinson EJ, Melton LJ III, Riggs BL (1997) Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a populationbased study. J Clin Endocrinol Metab 82:1522-1527
21. Orwoll ES, Bell NH, Nanes MS, Flessland KA, Pettinger MB, Mallinak NJ, Cain DF (1998) Collagen N-telopeptide excretion in men: the effects of age and intrasubject variability. J Clin Endocrinol Metab 83:3930-3935
22. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C (1998) Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281-2289
23. Fatayerji D, Eastell R (1999) Age-related changes in bone turnover in men. J Bone Miner Res 14:1203-1210
24. Del Campo MT, Gonzalez-Casaus ML, Aguado P, Bernad M, Carrera F, Martinez ME (1999) Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion. Osteoporos Int 9:449-454
25. Pi YZ, Wu XP, Liu SP, Luo XH, Cao XZ, Xie H, Liao EY (2006) Age-related changes in bone biochemical markers and their relationship with bone mineral density in normal Chinese women. J Bone Miner Metab 24:380-385
26. Sone T, Miyake M, Takeda N, Fukunaga M (1995) Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age-and sex-related changes and reference limits. Bone (NY) 17:335-339
27. Ravn P, Fledelius C, Rosenquist C, Overgaard K, Christiansen C (1996) High bone turnover is associated with low bone mass in both pre-and postmenopausal women. Bone (NY) 19:291-298
28. Ravn P, Rix M, Andreassen H, Clemmesen B, Bidstrup M, Gunnes M (1997) High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women. Calcif Tissue Int 60:255-260
29. Melton LJ III, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083-1091
30. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J (1999) The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 14:1583-1595
31. Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD (2001) Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 16:1642-1650
32. Chu P, Chao TY, Lin YF, Jankila AJ, Yam LT (2003) Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 41:1052-1059
33. WHO Scientifi c Group (2003) Prevention and management of osteoporosis. WHO Technical report series 921. WHO, Geneva
34. The committee for establishing the guideline for initiating pharmacologic treatment to prevent fragility fractures (2006) The guideline for initiating pharmacologic treatment to prevent fragility fractures (in Japanese). Osteoporosis Jpn 14:665-668
35. Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporosis Int Suppl 6:S55-S65
36. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone (NY) 34:187-194